CF2H: a cell-free two-hybrid platform for rapid protein binder screening.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41807394.
- Also identified by DOI 10.1038/s41467-026-69741-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Protein binders that detect, activate, inhibit, or otherwise modulate their targets are pivotal for biomedical applications. With the increasing accuracy and accessibility of de novo protein design, faster and cheaper experimental screening methods would democratize and accelerate the identification of high-affinity binders. Here we present Cell-Free Two-Hybrid (CF2H), a rapid and sensitive method for detecting high-affinity protein-protein interactions (PPI) that does not require cloning, protein purification nor high-end laboratory equipment. CF2H uses a dimerization-activated DNA binding domain (DBD) fused to prey and bait proteins to trigger transcription upon protein-protein interaction. We demonstrate that CF2H enables the detection of interactions between various types of target and binder proteins such as single-domain antibodies, DARPins, and de novo designed binders. We benchmark CF2H as a screening platform by validating previously reported binders for Mdm2 and discovering high-affinity binders targeting the checkpoint inhibitor PD-L1 in less than 24 hours. Finally, we show that CF2H can be used to characterize small-molecule modulators of PPI and detect protein biomarkers, opening the door for a new class of cell-free biosensors.
Medical subject headings
- Two-Hybrid System Techniques
- Protein Interaction Mapping